ACTION-I: TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk (clinicaltrials.gov) - Oct 28, 2026 - P2 | N=105 | Recruiting | Sponsor: Sun Yat-sen University | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor
|